NASDAQ · MDWD
MediWound financials
$13.80−0.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.0M | $20.2M | $18.7M | $26.5M | $23.8M | $21.8M | $31.8M | $3.4M | $2.5M | $1.6M |
| Gross profit | $3.3M | $2.6M | $3.6M | $13.2M | $8.8M | $7.5M | $19.9M | $1.3M | $918.0K | -$600.0K |
| Gross margin | 19.2% | 13.0% | 19.1% | 49.7% | 36.9% | 34.7% | 62.7% | 38.6% | 36.8% | −38.5% |
| Operating income | -$25.3M | -$19.4M | -$15.3M | -$8.3M | -$11.2M | -$8.8M | $4.5M | -$4.0M | -$13.7M | -$20.2M |
| Net income | -$23.9M | -$30.2M | -$6.7M | -$19.6M | -$13.6M | -$9.2M | $5.0M | -$1.1M | -$22.1M | -$18.9M |
| Net margin | −140.8% | −149.5% | −35.9% | −74.0% | −57.0% | −42.3% | 15.6% | −31.1% | −887.4% | −1212.1% |
| Diluted EPS | $-2.10 | $-3.03 | $-0.75 | $-3.93 | $-3.48 | $-2.38 | $1.26 | $-0.28 | $-6.65 | $-0.86 |
| EBITDA | -$23.4M | -$17.9M | -$14.0M | -$7.1M | -$10.0M | -$7.8M | $5.6M | -$3.4M | -$13.1M | -$19.6M |
| Operating cash flow | -$16.1M | -$13.6M | -$10.5M | -$11.9M | -$8.9M | -$6.9M | $8.3M | -$12.2M | -$16.5M | -$16.4M |
| Free cash flow | -$21.6M | -$19.9M | -$16.9M | -$11.9M | -$9.4M | -$7.8M | $7.5M | -$12.7M | -$17.5M | -$17.1M |
| Diluted shares | 11.4M | 10.0M | 9.0M | 5.0M | 3.9M | 3.9M | 3.9M | 3.9M | 3.3M | 21.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.8M | $9.2M | $11.9M | $33.9M | $11.0M | $17.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $870.0K | $612.0K | $1.4M | $2.2M | $2.4M | $2.4M |
| Total assets | $86.3M | $73.5M | $66.5M | $50.0M | $19.7M | $31.1M |
| Total liabilities | $42.6M | $42.3M | $34.9M | $39.1M | $24.3M | $23.8M |
| Shareholders' equity | $43.6M | $31.2M | $31.6M | $10.9M | -$4.6M | $7.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology